Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-18T09:46:40.466Z Has data issue: false hasContentIssue false

Lithium and carbamazepine in bipolar disorder

Published online by Cambridge University Press:  18 September 2015

P. Moleman*
Affiliation:
Institute for Clinical Psychiatric Research's GravenhageMoleman Research, Consultants on Human Psychopharmacology, Amerongen, The Netherlands
E.G.Th.M. Hartong
Affiliation:
Institute for Clinical Psychiatric Research's Gravenhage
C.A.L. Hoogduin
Affiliation:
Institute for Clinical Psychiatric Research's GravenhageDept. of Clinical Psychology, K.U. Nijmegen
T.G. Broekman
Affiliation:
Bureau Beta, Nijmegen, The Netherlands
W.A. Nolen
Affiliation:
Institute for Clinical Psychiatric Research's GravenhageDepartment of Psychiatry, University Medical Center Utrecht and Altrecht, Utrecht, The Netherlands
*
Moleman Research BV, Burg. Jhr. H. van den Boschstraat 11, 3958 CA Amerongen, The Netherlands

Abstract

Lithium is considered first choice in the prevention of prospective episodes in patients with bipolar disorder. However, efficacy is not satisfactory in all patients and side effects sometimes prevent the use of lithium. It is argued that efficacy in clinical practice may be less impressive than anticipated from clinical trials, and alternative treatments are beinu advocated increasingly for that reason, such as the anticonvulsants, carbamazepine and valproate.

Information

Type
Articles
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable